Skip to content
  • Thursday, 21 May 2026
  • 11:38 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • OrsoBio’s LXR Inverse Agonist Shows Promise for Hard-to-Treat Triglyceride Disorders, Paving New Path Beyond GLP-1 Dominance
Laboratory Automation & Robotics

OrsoBio’s LXR Inverse Agonist Shows Promise for Hard-to-Treat Triglyceride Disorders, Paving New Path Beyond GLP-1 Dominance

Lana Keisha Apr 14, 2026 0

OrsoBio, a specialized biotechnology firm dedicated to pioneering therapies for obesity and its associated metabolic conditions, is strategically charting a…

Read More
Laboratory Automation & Robotics

OrsoBio’s LXR inverse agonist shows promise for hard-to-treat triglyceride disorders

Lana Keisha Apr 3, 2026 0

OrsoBio, a specialized biotechnology company strategically focused on addressing obesity and its myriad related metabolic dysfunctions, is charting a course…

Read More
Laboratory Automation & Robotics

OrsoBio’s LXR inverse agonist shows promise for hard-to-treat triglyceride disorders

Lana Keisha Mar 26, 2026 0

OrsoBio, a specialized biotechnology firm dedicated to pioneering treatments for obesity and its associated metabolic disorders, is strategically charting a…

Read More
Laboratory Automation & Robotics

OrsoBio’s LXR inverse agonist shows promise for hard-to-treat triglyceride disorders and pioneering a new frontier in obesity therapeutics

Lana Keisha Mar 19, 2026 0

OrsoBio, a dynamic biotech enterprise dedicated to advancing novel therapies for obesity and a spectrum of obesity-related metabolic disorders, is…

Read More
UCB Acquires Neurona Therapeutics for Up to $1.15 Billion to Bolster Epilepsy Pipeline with Regenerative Cell TherapyThe Uncanny "Snuffleupagus" Fish Emerges from Australian Coral ReefsScience News: Empowering Public Understanding of Science, Medicine, and Technology Since 1921States Banning Abortion Show a Trend Away From Effective Miscarriage Treatment
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveHigh-Dimensional Topological Structures Discovered in Entangled Photons Offer New Framework for Quantum Information StabilityWater-in-Diesel Emulsion Technology Offers Significant Emissions Reduction Potential Without Engine Modification
Biotech Bi-Weekly Delivers Insight into Breakthrough Product Launches, Strategic Alliances, and Financial Shifts Shaping the IndustryPharma R&D Returns Soar to 7% Driven Almost Exclusively by GLP-1 Therapies, Deloitte Report RevealsAnalyzing Natural Speech Patterns Provides Crucial Indicators of Brain Health and Executive Function Across the LifespanTakeda Ordered to Pay $885 Million in Landmark "Pay-for-Delay" Drug Case, Faces Potential $2.5 Billion Liability
YOU MAY HAVE MISSED
Biotech & Genetic Research
Biotech Bi-Weekly Delivers Insight into Breakthrough Product Launches, Strategic Alliances, and Financial Shifts Shaping the Industry
Jia Lissa May 21, 2026
Laboratory Automation & Robotics
Pharma R&D Returns Soar to 7% Driven Almost Exclusively by GLP-1 Therapies, Deloitte Report Reveals
Lana Keisha May 21, 2026
Neuroscience & Brain Research
Analyzing Natural Speech Patterns Provides Crucial Indicators of Brain Health and Executive Function Across the Lifespan
Rifan Muazin May 21, 2026
Pharmaceutical R&D
Takeda Ordered to Pay $885 Million in Landmark "Pay-for-Delay" Drug Case, Faces Potential $2.5 Billion Liability
Teuku Ryan May 21, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ